Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767488657> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2767488657 endingPage "vi138" @default.
- W2767488657 startingPage "vi138" @default.
- W2767488657 abstract "Glioblastoma is a disease characterized by progressive decline in patients’ functional status and cognitive abilities. The EF-14 phase 3 trial demonstrated that adding TTFields to temozolomide (TTFields/TMZ) compared to temozolomide alone (TMZ) led to a significant increase in both progression free survival and overall survival of patients with newly diagnosed glioblastoma who had not progressed during their initial radiation therapy with TMZ. Time dependent differences in patients’ performance status and cognitive capabilities were protocol prespecified analyses. Time to deterioration (TTD) in performance status was measured using the Kaplan-Meier method considering a sustained decrease in Karnofsky performance score (KPS) of ≥10 points or death within 90 days of the last follow up an event. Patients without decline in KPS were censored at their last evaluation. TTD in cognitive function was measured using the Kaplan-Meier method considering a sustained decrease in Mini-Mental Status Score (MMSE) of ≥6 points or death within 90 days of the last evaluation of an event. Patients with a decline in MMSE of <6 points were censored at their last evaluation. TTD in KPS was similar to time to radiological disease progression and was significantly longer in patients treated with TTFields/TMZ than with TMZ alone (median 5.5 months vs 3.9 months; HR 0.84; p=0.0092). TTD in MMSE was longer than time to deterioration in KPS in both arms, and was significantly longer in patients treated with TTFields/TMZ than with TMZ alone (median 16.7 months vs 14.2 months; HR 0.81; p=0.012). Patients with compliance ≥75% with TTFields had significantly longer TTD in MMSE (p=0.0028) but not in KPS (p=0.652) compared to patients with compliance <75%. These results suggest that decline in performance status and cognitive capabilities are correlated with disease progression and extended by the addition of TTFields to TMZ." @default.
- W2767488657 created "2017-11-17" @default.
- W2767488657 creator A5017193696 @default.
- W2767488657 creator A5029517342 @default.
- W2767488657 creator A5030315115 @default.
- W2767488657 creator A5031998230 @default.
- W2767488657 creator A5037906439 @default.
- W2767488657 creator A5041531792 @default.
- W2767488657 creator A5086914791 @default.
- W2767488657 date "2017-11-01" @default.
- W2767488657 modified "2023-09-26" @default.
- W2767488657 title "NCOG-05. TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA" @default.
- W2767488657 doi "https://doi.org/10.1093/neuonc/nox168.566" @default.
- W2767488657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5692819" @default.
- W2767488657 hasPublicationYear "2017" @default.
- W2767488657 type Work @default.
- W2767488657 sameAs 2767488657 @default.
- W2767488657 citedByCount "0" @default.
- W2767488657 crossrefType "journal-article" @default.
- W2767488657 hasAuthorship W2767488657A5017193696 @default.
- W2767488657 hasAuthorship W2767488657A5029517342 @default.
- W2767488657 hasAuthorship W2767488657A5030315115 @default.
- W2767488657 hasAuthorship W2767488657A5031998230 @default.
- W2767488657 hasAuthorship W2767488657A5037906439 @default.
- W2767488657 hasAuthorship W2767488657A5041531792 @default.
- W2767488657 hasAuthorship W2767488657A5086914791 @default.
- W2767488657 hasBestOaLocation W27674886571 @default.
- W2767488657 hasConcept C126322002 @default.
- W2767488657 hasConcept C143998085 @default.
- W2767488657 hasConcept C2776194525 @default.
- W2767488657 hasConcept C2777389519 @default.
- W2767488657 hasConcept C2779134260 @default.
- W2767488657 hasConcept C2779483572 @default.
- W2767488657 hasConcept C2984863031 @default.
- W2767488657 hasConcept C502942594 @default.
- W2767488657 hasConcept C509974204 @default.
- W2767488657 hasConcept C71924100 @default.
- W2767488657 hasConceptScore W2767488657C126322002 @default.
- W2767488657 hasConceptScore W2767488657C143998085 @default.
- W2767488657 hasConceptScore W2767488657C2776194525 @default.
- W2767488657 hasConceptScore W2767488657C2777389519 @default.
- W2767488657 hasConceptScore W2767488657C2779134260 @default.
- W2767488657 hasConceptScore W2767488657C2779483572 @default.
- W2767488657 hasConceptScore W2767488657C2984863031 @default.
- W2767488657 hasConceptScore W2767488657C502942594 @default.
- W2767488657 hasConceptScore W2767488657C509974204 @default.
- W2767488657 hasConceptScore W2767488657C71924100 @default.
- W2767488657 hasIssue "suppl_6" @default.
- W2767488657 hasLocation W27674886571 @default.
- W2767488657 hasLocation W27674886572 @default.
- W2767488657 hasLocation W27674886573 @default.
- W2767488657 hasOpenAccess W2767488657 @default.
- W2767488657 hasPrimaryLocation W27674886571 @default.
- W2767488657 hasRelatedWork W1967988339 @default.
- W2767488657 hasRelatedWork W2022976025 @default.
- W2767488657 hasRelatedWork W2036862336 @default.
- W2767488657 hasRelatedWork W2067635850 @default.
- W2767488657 hasRelatedWork W2243195943 @default.
- W2767488657 hasRelatedWork W2740663609 @default.
- W2767488657 hasRelatedWork W2898414990 @default.
- W2767488657 hasRelatedWork W2995260688 @default.
- W2767488657 hasRelatedWork W3194058763 @default.
- W2767488657 hasRelatedWork W4205109938 @default.
- W2767488657 hasVolume "19" @default.
- W2767488657 isParatext "false" @default.
- W2767488657 isRetracted "false" @default.
- W2767488657 magId "2767488657" @default.
- W2767488657 workType "article" @default.